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Primary radiotherapy as an alternative management for adenocarcinoma of the endometrium 
was chosen for 117 patients treated at the University of Michigan Medical Center and 
University of Virginia Medical Center. Cases were selected for radiation because of con- 
traindications to surgery (52.2%) or by protocol for disease outside the endometrium 
(47.8%). An overall 5-year actuarial survival rate of 49.6% was attained for all stages, with 
55% 5-year survival for disease limited to the uterus or cervix. Stage and grade were the 
most significant risk factors. The addition of external-beam irradiation did not improve 
local failure rates or survival. Heyman’s uterine packing technique was slightly more 
successful than uterine “line sources” in controlling local disease (P = 0.08). Treatment- 
related mortality (0.8%) and morbidity (6.8%) were minimal. Surgery, whenever possible, 
remains the “best standard therapy” but the radiotherapeutic alternative is of significant 
benefit for those deemed nonsurgical candidates. 
INTRODUCTION 
Forty years have passed since Professor Heyman presented the results of the 
radiotherapeutic treatment of adenocarcinoma of endometrium and demonstrated 
the radium packing technique to be, in essence, as efficacious as total hysterectomy 
in the successful management of this malignancy [l]. Much has changed in 
medicine since then. Treatment results with surgery are now universally accepted 
as superior to radiation therapy alone. There remains, however, a small group 
of patients with corpus cancer who even today have contraindications to con- 
ventional management (i.e., TAH/BSO) because of either significant medical 
complicating factors or unresectable lesions. Although gynecologic surgeons and 
gynecologic oncologists continue to need alternatives to abdominal hysterectomy 
in the treatment of these selected high-risk patients, relatively few large series 
that incorporate modern radiotherapy technology are available to assess primary 
radiation for endometrial cancer [2-41. A retrospective clinical review is therefore 
reported to 
’ To whom requests for reprints should be addressed. 
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(1) examine the selection of patients for therapy with radiation alone, 
(2) evaluate the success of primary radiation therapy, 
(3) assess the radiotherapeutic methods most successful in achieving local 
control, 
(4) assess the influences of megavoltage external therapy that has developed 
since Heyman’s initial report, 
(5) assess the cost of therapy in terms of treatment morbidity and mortality. 
MATERIALS AND METHODS 
To maximize the study population, the clinical experience of the gynecologic 
oncology units of the University of Michigan and the University of Virginia were 
combined. From 1950 through 1979, 126 patients with endometrial adenocarcinoma 
were treated with radiation therapy alone at the two institutions. Histopathologic 
review excluded 9 patients who on reevaluation had either hyperplasia (5 cases) 
or metaplasia (4 cases). In the remaining 117 cases, 58 separate variables were 
abstracted and subsequently computer analyzed. 
Radiation alone was chosen based on general clinical characteristics that predicted 
poor tolerance of standard therapy, i.e., hysterectomy, although at one time all 
Stage II corpus cancers were selected for radiation therapy at both institutions. 
In addition, patients with Stage III and Stage IV disease were treated with 
radiation for control of pelvic disease. Six patients had prior pelvic radiation 
therapy (4 for malignancy, 2 for benign conditions) and were retreated with 
radiation after they developed a uterine adenocarcinoma. 
The pretreatment radiotherapy prescriptions, although quite varied, were all 
designed to at least effect local control. The treatment schema fell into three 
broad categories. Intracavitary radium application alone utilizing either Heyman’s 
capsules or Campbell’s capsules, or uterine tubes and vaginal vault sources 
(rarely whole-length vaginal cylinders) were prescribed to deliver 6000-7000 rad 
to point A or 5000-6000 mg/hr in one or two packings. If a uterine tube was 
used, loading of the sources was such that a more cylindrical dose distribution 
was obtained, in contrast to standard loading for cervical lesions 151. A second 
approach was to use intracavitary radium application to deliver 3000-4000 rads 
to point A or 4000-5000 mg/hr coupled with external-beam therapy to the whole 
pelvis, 4000-5000 rad total midline dose over 4 to 5 weeks. Finally some patients 
were treated with whole-pelvic irradiation only, usually to a dose of 5000-6000 
rad total midline dose over 5 to 10 weeks. 
RESULTS 
General Observations 
Of the 117 patients treated with radiation therapy alone, only about one-half 
were Stage I (Table I), about 35% were Stage II, and about 12% had extrauterine 
disease (Stages III and IV). The corresponding actuarial survival probability 
(Berkson and Gage method) by stage, although not surprising, is dramatically 
significant at P greater than 0.0001 using the Cox’s life table regression model, 
and represented a powerful confounding influence when analyzing other variables 
affecting outcome. The next most powerful determinant of survival probability 
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TABLE 1 
STAGE DISTRIBUTION AND ACTUARIAL SURVIVAL PROBABILITY FOR 117 PATIENTS TREATED WITH 
RADIOTHERAPY ONLY 
Patients 
Stage Number % 
IA 35 29.9 
IB 26 22.2 
II 42 35.9 
III 10 8.5 
IV 4 3.4 










in this series was histologic grade. It was more significant than histologic type. 
Grading of the tumors incorporated characteristics of cytoplasmic and nuclear 
size, variability, and atypicality, and not pattern of growth alone [6]. Less than 
one-half of the patients had well-differentiated lesions while one-fourth of the 
cases were poorly differentiated (Table 2). Only 32% of the patients with G-III 
lesions survived their disease, compared to 57% for patients with more favorable 
differentiation (P = 0.05). Table 2 collates survival by grade in patients with 
disease limited to the uterus, i.e., Stages I and II. 
The histologic types encountered (Table 3) reflect a broad spectrum. Of interest, 
there was a history of prior pelvic RT noted in 2 of 12 cases of clear cell 
adenocarcinoma, in 1 of 13 cases of papillary carcinoma, but in only 3 of 75 
cases of the “endometrial”-type adenocarcinoma. Predicted 5-year survival for 
the “endometrial” adenocarcinoma was 52.4%, for adenosquamous carcinoma, 
44.7%, and for clear cell adenocarcinoma, 37%. Papillary carcinoma had an 
unexpected survival prediction of 70.08% but 54% of these cases were Stage I. 
Pretreatment uterine size (estimated in equivalent gestational age/size in weeks) 
ranged from normal to 20 weeks for the group, with a median of 8 weeks. Uterine 
sounding values ranged from 4 to 16 cm (median 8 cm). Corpus dimensions by 
TABLE 2 
HISTOLOGIC TYPE AND CYTOLOGIC GRADE OF THE 117 PATIENTS TREATED WITH RADIOTHERAPY ALONE~ 
Cytologic grade 
Histologic type Cl G2 G3 Total 
Endometrial 34 






L? Eight patients, data not known. 
23 13 70 
1 3 11 
5 1 13 
1 11 12 
1 1 2 
0 1 1 
31 30 109 
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TABLE 3 
PATIENTS WITH DISEASE LIMITED TO THE UTERUS: 
SURVIVAL BY STAGE AND GRADE 




















sounding seemed retrospectively to have influenced choice of therapy; i.e., smaller 
uteri were generally chosen for intracavitary treatment alone, and therapy for 
larger uteri more often incorporated internal and external therapy or external 
therapy alone (correlation P = 0.05). Uterine size estimates, however, showed 
no correlation with choice of radiation therapy technique. In addition the type 
of therapy chosen appeared to be independent of the histologic grade of the 
tumor, and the histologic type of tumor. The stage of endometrial cancer prior 
to treatment did show a significant influence on choice of therapy (P = 0.05) 
with the more advanced stages relying primarily on external beam alone. 
Clinical Characteristics with “Medical Contraindications” to Surgery 
The 61 cases of Stage I endometrial carcinoma in this study were all selected 
for radiation therapy purely on the basis of predicted unacceptable morbidity 
and mortality from surgery. The clinical profile of these patients (Table 4) indeed 
reflects a medically high-risk group. Over one-half of these patients were above 
the seventh decade of life and because of their general health problems over 
one-half were confined to bed for the greater part of each day. The typical patient 
had at least three of the medical diagnoses tabulated. 
Twelve of the sixty-one patients had a prior history of cancer (four presumed 
cervix, three breast, two lymphoma/leukemia, one each colon, melanoma, sinus) 
and three additional patients had concominant second primaries (two breast, one 
thyroid). One patient developed gastric carcinoma after successful treatment of 
her endometrial cancer. Fifteen of these sixteen patients died of malignancy, but 
only five died of progressive uterine disease. 
Although 22 of the patients with medical contraindications to surgery succumbed 
to endometrial malignancy, 31 (51%) died as a result of other conditions, free 
of cancer. Mean survival of those dying of malignancy was 49.3 months, while 
mean survival of those dying of other nonmalignant conditions cancer free was 
71.2 months (P = 0.08). 
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TABLE 4 
CLINICAL PROFILE OF THE 61 PATIENTS SELECTED 
FOR PRIMARY RADIOTHERAPY BECAUSE OF 
MEDICAL CONTRAINDICATIONS~ 
Patients 
Medical conditionb Number % 
High blood pressure 44 72 
Obesity 29 48 
Other’ 28 46 
Diabetes mellitus 27 44 
Coronary disease 22 36 
Pulmonary disease 6 10 
Cerebral vast disease 5 8 
Dementia 3 5 
’ Median age was 71.7 years (range 41-87) and 
median performance status was 3 (GOG scale). 
b Many patients had more than one condition. 
’ Other includes patients with one or more of 
the following: 15 with prior malignancy, 10 with 
arthritis, 10 with congestive heart failure, 3 with 
deep vein thrombophlebitis, and 3 with pulmonary 
embolus. 
Analysis of Treatment Success and Failure 
In order to analyze treatment factors that influenced local control and survival, 
patients with disease clinically confined to the uterus or cervix (Stages I and II) 
were grouped together (N = 103). Patients with extrauterine disease (Stages III 
and IV) in this series had a predicted 5-year survival of only 13% contrasted to 
55% for those with disease limited to the uterus and/or cervix (P > 0.005). 
Although 38.8% of Stage I and II cases died of disease, 33% died of other causes, 
tumor free. Table 5 illustrates the pattern of treatment failure in Stage I and II. 
Disease recurrences in the uterus, cervix, upper vagina, or pelvic side wall (pelvic 
recurrence) strongly correlated with the likelihood of extrapelvic (groin, intraab- 
dominal, liver or lung) metastatic disease as well (P > 0.01). Of the patients 
TABLE 5 
PATTERN OF RECURRENCES IN 103 PATIENTS WITH STAGE I AND XI ADEN~CARCINOMA OF THE CORPUS 
TREATED WITH RADIOTHERAPY ALONE’ 
Extrapelvic recurrence 
Pelvic recurrence No Yes Total 
No 54 11 65 
Yes 12 14 26 
Total 66 25 91 
a Excluded are 9 cases of recurrence but site not known and 3 cases of persistent disease. 
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with recurrent disease, the median recurrence-free interval was 11.1 months after 
initial treatment. 
The local failure (defined as locally persistent or locally recurrent tumor within 
the pelvis) is chosen as the best measure of success of the various radiotherapeutic 
techniques utilized in the treatment of patients with corpus cancer limited to the 
uterus in this series. There were 3 patients with persistent pelvic disease after 
radiotherapy and 26 central or pelvic side wall recurrences (9 cases the site of 
recurrence is not known). Successful control of local disease carried a 70% 5- 
year survival probability, while method failure predicted a dismal 19% survival 
(P = 0.001). 
Using the local failure assessment, there was no advantage of statistical sig- 
nificance among the general radiotherapeutic methods utilized, although the ap- 
proach of external beam alone gave the poorest results (Table 6). The use of 6- 
8 MeV LINAC photons (in 16 patients) did not improve local failure rates when 
contrasted to “Orthovoltage” (15 patients) or cobalt-60 therapy (26 patients). 
Heyman’s packing technique was utilized in 55 of the 111 intracavitary ap- 
plications in the treatment of 103 patients with disease limited to the uterus, 
while 56 patients had “line sources” in the uterus. Although local disease was 
more often successfully controlled with the Heyman’s approach, the difference 
only approached statistical significance (P = 0.08). Vaginal sources were used 
in only 66 of the 111 applications. Sixty-two of these sixty-six were via ovoids 
or colpostats, and the remainder were “line sources” in the vagina. There was 
no difference in rates of local disease control with either approach. 
Recreation of precise radiation dosimetry was not possible because sufficient 
technical simulation data was not always available. Determination of dose/response 
relationships or threshold doses for local control was also impossible because 
of the variation and expression of the intracavitary exposures (recorded either 
in rad to Point A or in milligram/hour). 
Outcome of Patients with Prior Radiation Therapy 
A special note is made of the six patients treated with radiation therapy for 
adenocarcinoma of the endometrium who had had prior pelvic irradiation. Details 
TABLE 6 
CORRELATION OF RADIOTHERAPEUTIC METHODS WITH METHOD OUTCOME” IN THE 103 CASES OF STAGE 
I AND II UTERINE ADEN~CARCINOMA 
Radiotherapeutic methods 
Intracavitary 
Method outcome Intracaviatry and external External Total 
Success 29 31 5 65 
Failure 12 13 4 29 
Total 42 44 9 94 
’ Method failure is defined as “locally persistent or locally recurrent disease” (nine cases, local 
status not known). 
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of their original radiation were not available. There were four patients with Stage 
I disease, one patient with Stage II disease, and one with Stage IV disease. 
There was only one tumor-free survivor at 5 years. Three cases were managed 
with intracavitary alone (5000 mg/hr) and one of these died of recurrent pelvic 
disease at 20 months while the remaining two died of medical causes, tumor 
free, at 2 and 60+ months. External beam alone was used in two patients and 
both had persistent pelvic disease and subsequently died of malignancy at 8 and 
16 months. The final patient was treated with 5000 rad whole pelvic external 
beam and an intracavitary application of 3000 rad to point A, and she is alive, 
disease free, at 22 months. No major radiation morbidity was noted in any patients 
within the observation periods. 
Management of Radio Persistent or Radio Recurrent Disease 
There were three patients with persistent disease and 46 patients with recurrent 
metastatic disease (any site) among the 103 cases of Stage I and II corpus cancer. 
Eighteen of these patients received no further therapy and all died of progressive 
malignancy by 12 months after the recurrence was detected. Thirty-one patients 
with recurrence received some form of additional therapy but 58% were dead 
of disease by 2 years and only 15% were predicted to be alive at 5 years. 
Progestational therapy alone was the most common treatment for recurrence and 
was used in seven patients. Four patients were managed with progestational 
agents and cytotoxic drugs; three patients received progestational agents and 
“palliative’ ’ radiation therapy (to extrapelvic metastases). Four patients were 
treated solely with “palliative” radiation therapy (to extrapelvic sites). Finally, 
two cases of recurrence were managed with cytotoxic drugs only and two patients 
with persistent or recurrent local disease had subsequent surgery. In nine cases 
the management of recurrence was not specifically known. Overall, 43 of the 49 
cases of persistent or recurrent disease died of progressive malignancy and only 
three died of other causes, disease free. 
Complications of Therapy 
A massive pulmonary embolus during a radium application accounted for the 
only treatment-related mortality in this series of 117 patients. Two patients required 
hospitalization for medical management of radiation proctitis/enteritis but did not 
require surgery. Both patients had received their external-beam therapy via cobalt 
unit and both were long-term survivors, free of disease. Two additional patients 
developed radiation bowel injury subsequently requiring surgery. One patient 
developed a rectal stricture after treatment with a 250 kV unit and intracavitary 
radium. She underwent colostomy diversion and died of myocardial infarction 
11 months post-treatment. A second patient, also treated with 250 kV external 
unit in addition to intracavitary radium, developed a complex enterovaginah 
rectovaginal fistula, and underwent successful surgical management and survived 
20 years. 
There were also a number of other complications that occurred during therapy 
which subsequently influenced the choice and execution of therapy. One patient 
developed staphylococcal pneumonia during external-beam therapy and was too 
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ill for an intracavitary treatment. Two cases of pyometria required drainage and 
antibiotics, but intracavitary radium packings were then performed without incident. 
Endometritis during an intracavitary radium application occurred in one case, 
and again after successful medical management repacking was accomplished to 
complete treatment. Finally, two patients had uterine perforation at the time of 
attempted intracavitary radium application. In both cases, packing was not re- 
attempted. Of the six cases of complications during therapy, four subsequently 
died of their uterine malignancy. 
DISCUSSION 
The fundamental principle of management of adenocarcinoma of the endometrium 
is to remove the uterus, tubes, and ovaries. Numerous reports [7-91 predict an 
89-91% 5-year survival for Stage I disease managed by surgery. Although recent 
reviews show a 65-78% survival for patients managed with radiation therapy 
alone [2-41, clearly this represents a less desirable approach for primary treatment. 
It is not the intent of the authors to advocate radiation as the “standard best 
management” but to reaffirm and clarify its invaluable place as an alternative 
treatment for selected patients with contraindications to surgery. Indeed, at this 
time, radiotherapy is the only viable alternative. Chemotherapy or hormonal 
manipulation produce only rare sustained “complete responses” although trials 
have been limited to recurrent or advanced disease 1101. 
Significant advances in all areas of general medicine have decreased the number 
of “medically inoperable” cases, and the assessment of medical risk can only 
be made on individual basis by the attending physician. The mean predicted 
survival for a woman age 70 is about 170 months [Ill. Although no standard 
selection criterion was defined, patients in this series having apparent successful 
management of their corpus cancer only survived a mean of 71.2 months, dem- 
onstrating the impact of their complicating medical conditions. 
Prior or concomitant malignancy should also be considered in selection of 
therapy for uterine cancer. The high incidence (24%) of other malignancies is 
not surprising in this age group, but it is significant that tumor deaths in patients 
with second primaries were most often due to the nonuterine cancer (10/15). 
Performance status is also a valuable criterion in selection of patients for primary 
radiation therapy. It reflects the overall health of the patient and the impact of 
medical illnesses on the ability of the patient to function normally. Radiotherapy 
should cause the least deterioration of a compromised performance status. 
This series represents a unique group of patients with endometrial cancer. 
Only 52% of the cases were Stage I; only 64% of the cases had “endometrioid” 
type of adenocarcinoma; only 44% of the cases had Grade I lesions. In this 
context, 49.6% 5-year predicted actuarial survival for the 117 patients is not 
surprising. 
Because of the impact of associated medical conditions and because of the 
inability to control extrapelvic disease even with “standard surgical management,” 
the focus of therapy should be effective local pelvic control. The overall local 
failure rate (for disease limited to the uterus) was 30.8% (29/94). The available 
data for analysis of these 94 patients would indicate that the addition of external- 
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beam therapy to the intracavitary approach did not significantly improve local 
control or increase survival. Although several reports [2,12] support the use of 
external beam as part of a primary radiation schema for corpus cancer, others 
[4,13] consider the radium packing the most important component. 
External-beam therapy is designed to increase the pelvic side wall (i.e., pelvic 
nodal) doses. This is done, however, at the expense of the central intracavitary 
radium dose. “Sterilization” of the uterine cavity of tumor has been reported 
in 59-78010 of the cases reviewed by Strickland [13] and Joelsson et al. [14] when 
preoperative intracavitary radiation was used. This is contrasted to only a 38.9% 
sterilization rate when preoperative external-beam radiation was used [ 151. Com- 
promise of the intracavitary packing dose therefore may decrease uterine control 
with primary radiation therapy. 
The packing technique itself does deliver radiation to the side wall or pelvic 
nodal areas and this can be as high as 3000-4000 rad as demonstrated by Landgren 
et al. [41 Moreover, although recent emphasis has been placed on nodal disease 
associated with adenocarcinoma of the endometrium, estimates of pelvic nodal 
metastases in Stage I and II cases (all grades and histologic types) are a relatively 
low 10% [16]. Clearly the main treatment emphasis for the majority of patients 
with disease confined to the uterus should be the uterus itself. 
Since, in this series, the addition of external irradiation did not improve local 
failure rates or survival, it follows that no significant advantage was shown when 
megavoltage external radiation units were used to deliver the external-beam 
therapy. This agrees with the observations of Wilson et al. [15]. 
The Heyman;packing technique, with large endometrial dosages, appeared to 
give better results than the use of “line sources” in the uterus, but the advantages 
were of borderline statistical significance in this series. The Heyman approach 
requires more care and skill to avoid complications [17]. Another problem with 
the Heyman technique is that dosimetry curves can only be approximated because 
of the unknown “filtering” that occurs due to the capsules themselves [18]. 
Recurrent disease, in this series, was almost universally fatal, and no specific 
form of management emerged as superior. It is felt that the general compromised 
medical condition of the patients reviewed was not conducive to aggressive 
chemotherapy which may explain in part the dismal outcome, but agents with 
high sustained activity against endometrial carcinoma are still not available [19]. 
The “cost” of radiotherapy was a treatment mortality rate of 0.8%, an overall 
complication rate of 6.8%, and a 3.4% incidence of major complications (i.e., 
those requiring hospitalization or surgery at some period after treatment). The 
impression is that the use of “megavoltage” external therapy led to fewer significant 
complications. 
SUMMARY 
The present series of 117 patients with adenocarcinoma of the endometrium 
treated by radiation therapy alone continues to confirm that surgery, whenever 
possible, gives superior results. In the selected high-risk patient, however, results 
of primary irradiation are quite acceptable especially in view of minimal treatment- 
related morbidity and mortality. Selection of patients for primary radiotherapeutic 
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treatment must be individualized. The cornerstone of successful radiation treatment 
remains intracavitary radiation. The Heyman packing technique may offer an 
advantage in local control, but the technique is more difficult and not universally 
applicable. Until more active hormonal or chemotherapeutic agents evolve, radiation 
therapy is the on/y alternative for the management of adenocarcinoma of the 
endometrium in patients with contraindications to surgery. 
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